ACHIEVE LIFE SCIENCES, INC. — Director's Dealing 2015

Jan 30, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ONCOGENEX PHARMACEUTICALS, INC. (OGXI)
CIK: 0000949858
Period of Report: 2015-01-27

Reporting Person: Cormack Scott Daniel (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-01-27	Common Stock	M	20100	$0.00	Acquired	108263	Direct
2015-01-30	Common Stock	F	9206	$2.11	Disposed	99057	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-01-27	Restricted Stock Unit (RSU)	$	M	20100	Disposed	2015-07-01	Common Stock (20100)	Direct

Footnotes

F1: Represents shares of common stock acquired upon settlement of the restricted stock units ("RSUs") listed in Table II.

F2: Represents shares of common stock that have been withheld by the issuer to satisfy the tax liability in connection with the settlement of RSUs.

F3: Each RSU represents a contingent right to receive one share of the issuer's common stock at settlement.

F4: Pursuant to the terms of the RSU, the total underlying shares vest when certain performance criteria relating to the issuer are met.

F5: The RSUs expire 30 days from the date they vest.